Abstract
Running infusion of Cyclocytidine (CC) (2, 2'-anhydro-1-β-D-arabinofuranosylcytosine hydrochloride) was performed in 25 patients of acute leukemia (20 cases of acute myelogenous leukemia, 3 of acute erythroleukemia and 2 of blastic crisis of chronic myelogenous leukemia).
The chemotherapeutic schedules were as follows
Regimen I: CC 10 mg/kg i.v. and prednisolone 30 mg p.o. daily.
Regimen II: CC 10 mg/kg i.v., 6-MP 100mg p.o. and prednisolone 30 mg daily.
Regimen III: 3-day courses of CC 10∼20 mg/kg and daunorubicin 20 mg at weekly intervals. 6-MP and prednisolone were administered as Regimen II.
Regimen IV: Vincristine 2mg, and CC 20 mg/kg for 3 consective days at weekly intervals. 6-MP and prednisolone were administered as Regimen II.
One patient with AML attained complete remission by Regimen I. The same results were obtained in 30% by Regimen II, 50% by Regimen III and 75% by Regimen IV. Of 14 AML patients who had received no prior treatment, 9 attained complete remission and 1 attained partial remission.
Pain of parotid glands was one of the most frequent side effects in the patients treated with 20 mg/kg of CC. Gastrointestinal disturbances were less than those by cytosine arabinoside. In 3 patients vertigo and orthostatic hypotension were observed.
The median survival from the time of onset in 20 AML patients treated with CC was 9 months or more.
